Lumvoa and Tepezza for thyroid eye disease
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.03.93 alerts
Get alerted when Policy 05.03.93 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Lumvoa (veligrotug-vvze) and Tepezza (teprotumumab-trbw) to treat thyroid eye disease. Coverage applies when product-specific clinical, specialist-prescriber, documentation, and treatment-history requirements are met, subject to the member's benefit contract.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.